AbbVie Reveals Positive Data for Eczema and Weight Loss Candidates
AbbVie Inc. (NYSE:ABBV) announced clinical trial data on Wednesday for two pipeline candidates, highlighting progress in its immunology and metabolic disease portfolios. The pharma giant shared encouraging Phase 2
AbbVie tested two new medicines and got good results. When a big drug company shows its medicines work, people watch to see if profits might grow later.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.